PULM (Pulmatrix Inc) Net Profit

Corporate emblem and logo of pulmatrix.com (PULM)

Patent protection for the iSPERSE platform creates a significant barrier to entry for competitors, which supports the current profit levels of Pulmatrix, Inc. (PULM). The value of -0.00 reflects the latest metric level while the business relies on grants and trials in the absence of regular sales. In the future, the R&D model will enable the collection of royalties from pharma behemoths, ensuring high margins without marketing expenditures.

PULM (Pulmatrix) Company Net Income history from 07/04/2022 to 10/29/2026

Financial and market metric breakdowns for Pulmatrix (PULM)

- price and consensus price forecast:
Stock Quotes Pulmatrix Corporation|PULM - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Pulmatrix Corporation|PULM - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Pulmatrix|PULM - Company Book Value|Market-to-Book Ratio pulmatrix.com|PULM - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Pulmatrix, Inc.|PULM - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Pulmatrix Inc|PULM - Company Aggregate Debts|Debts to Book Value Pulmatrix Corporation|PULM - Company Long-Term Debt|Company Short-Term Loans and Borrowings Pulmatrix|Critical Liquidity Ratio pulmatrix.com
- net income and valuation multiples indicators:
PULM - Net Income
Fundamental valuation:PULM Pulmatrix Corporation
Flagship merchandise of Pulmatrix Inc

The security of developing inhalation drugs within the US legal framework minimizes geopolitical risks, creating a stable foundation for the business. Analyzing the current net result of Pulmatrix, Inc. (PULM), an investor sees daily profit accruals that bridge the gaps between quarterly reports, confirming the asset's cash stability and allowing for an objective assessment of the real yield of Pulmatrix, Inc. (PULM) without the risk of overpaying at the peak.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|AQST (Aquestive Therapeutics Inc) - Profit After Tax|SCPH: Net Income|TECX - Net Profit|Tonix Pharmaceuticals (TNXP) - Company Net Income|SXTC (China SXT Pharmaceuticals, Inc.) - Company Net Income|Company Net Income Eupraxia Pharmaceuticals, Inc.|Net Income BioHarvest Sciences, Inc. (BHST)|Net Profit EXOZ|Net Profit oramed.com (ORMP)|Entera Bio - Net Income|Profit After Payment of Taxes HYFT (ipatherapeutics.com)|ABVC - Company Net Income|Final Profit CPIX (Cumberland Pharmaceuticals Inc)|QNTM: Net Profit|FGEN - Net Financial Result|Net Income TELO|Company Profit RANI (Rani Therapeutics Inc)|Net Income SNYR (Synergy CHC Corp)|RLYB (rallybio.com) - Final Profit|Net Profit LEXX (Lexaria Bioscience Corp.)|Net Financial Result Pheton Holdings Limited (PTHL)|APM - Company Net Income|LYRA (lyratherapeutics.com) - Company Profit|IBO: Net Profit|Net Income TNF Pharmaceuticals, Inc.|Net Income YCBD|PainReform Corp (PRFX) - Net Financial Result|Company Net Income Altamira Therapeutics (CYTO)|LIPO: Profit After Tax|OptiNose - Net Income|Net Profit Pieris Pharmaceuticals Inc PIRS|PROC - Company Net Income|PTPI: Company Net Income|Qilian International (QLI) - Company Net Income|Net Income acelyrin.com|Company Net Income TFF Pharmaceuticals, Inc.